| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 8943967 | Vaccine | 2018 | 8 Pages | 
Abstract
												Following PCV7/PCV13 introduction, rates of episodes caused by VT13 were substantially reduced in all 3 groups. However, differences in age distribution, serotype replacement and specific serotype decrease suggest different pathogenesis and host susceptibility between the 3 entities.
											Keywords
												
											Related Topics
												
													Life Sciences
													Immunology and Microbiology
													Immunology
												
											Authors
												Shalom Ben-Shimol, Noga Givon-Lavi, Galia Grisaru-Soen, Orli Megged, David Greenberg, Ron Dagan, On behalf of the Israel Bacteremia and Meningitis Active Surveillance Group On behalf of the Israel Bacteremia and Meningitis Active Surveillance Group, 
											